Prevalence of atrial fibrillation and eligibility for anticoagulants in the community

Lancet

Volumn 352, Issue 9135, 1998, Pages 1167-1171

  Sudlow, Mark ^a,b   Thomson, Richard ^b   Thwaites, Barnaby ^c   Rodgers, Helen ^a,b   Kenny, Rose Anne ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c WANSBECK GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR RISK; DRUG USE; ELECTROCARDIOGRAPHY; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PRIORITY JOURNAL; STROKE;

EID: 0032505605     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)01401-9     Document Type: Article

References (29)

1. 1 The Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 1991; 84: 527-39.
2. 2 Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991; 18: 349-55.
3. 3 Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. Lancet 1989; i: 175-79.
4. 4 The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990; 323: 1505-11.
5. 5 EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-62.
6. 6 Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation: Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992; 327: 1406-12.
7. 7 Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994; 154: 1449-57.
8. 8 Lake FR, Cullen KJ, de Klerk NH, McCall MG, Rosman DL. Atrial fibrillation and mortality in an elderly population. Aust N Z J Med 1989; 19: 321-26.
9. 9 Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol 1994; 74: 236-41.
10. 10 Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-88.
11. 11 Sudlow CM, Rodgers H, Kenny RA, Thomson RG. Service provision and use of anticoagulants in atrial fibrillation. BMJ 1995; 311: 558-60.
12. 12 Lip GYH, Golding DJ, Nazir M, Beevers DG, Child DL, Fletcher RI. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br J Gen Pract 1997; 47: 285-89.
13. 13 Wheeldon NM, Tayler DI, Anagnostou E, Cook D, Wales C, Oakley GDG. Screening for atrial fibrillation in primary care. Heart 1998; 79: 50-55.
14. 14 Hill JD, Mottram EM, Killeen PD. Study of the prevalence of atrial fibrillation in general practice patients over 65 years of age. J R Coll Gen Pract 1987; 37: 172-73.
15. 15 Sudlow M, Rodgers H, Kenny RA, Thomson R. Population based study of use of anticoagulants among patients with atrial fibrillation in the community. BMJ 1997; 314: 1529-30.
16. 16 Thomson RG, McElroy H, Sudlow M. Guidelines on anticoagulant treatment in atrial fibrillation in Great Britain: variation in content and implications for treatment. BMJ 1998; 316: 509-13.
17. 17 Glasziou PP, Irwig LM. An evidence based approach to individualising treatment. BMJ 1995; 311: 1356-59.
18. 18. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation I: clinical features of patients at risk. Ann Intern Med 1992; 116: 1-5.
19. 19 The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation: II: echocardiographic features of patients at risk. Ann Intern Med 1992; 116: 6-12.
20. 20 The Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity fixed dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996; 348: 633-38.
21. 21 The Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study. J Stroke Cerebrovasc Dis 1995; 5: 147-57.
22. 22 Halperin JL. Prospective identification of atrial fibrillation patients at low risk of stroke during treatment with aspirin: the SPAF-III Aspirin Low-Risk Cohort Study. Circulation 1997; 96 (Suppl 1): 1564.
23. 23 Man-Son-Hing M, Laupacis A, O'Connor A, et al. Warfarin for atrial fibrillation: the patient's perspective. Arch Intern Med 1996; 156: 1841-48.
24. 24 Petrie JC, O'Brien ET, Littler WA, de Swiet M. Recommendations on blood pressure measurement. BMJ 1986; 293: 611-15.
25. 25 Breeze E, Maidment A, Bennett N, Flatley J, Carey S. Health survey for England 1992: a survey carried out by the Social Survey Division of OPCS on behalf of the Department of Health. London: HM Stationery Office, 1994.
26. 26 O'Mahoney PG, Robson R, Rodgers H, James OFW, Thomson RG. Validation of a population screening questionnaire to assess prevalence of stroke. Stroke 1995; 26: 1334-37.
27. 27 Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendation regarding quantitation in M-mode echocardiography: results of a survey in echocardiographic measurements. Circulation 1978; 58: 1072-83.
28. 28 Cochran WG. Sampling techniques. New York: John Wiley, 1977: 52.
29. 29 Gustafsson C, Asplund K, Britton M, Norrving B, Olsson B, Marke LA. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. BMJ 1992; 305: 1457-60.